Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Trials
- 0
- Subs
- 0
- People
- 0
- Links
- 0
Executive Summary
AI synthesisSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is a Chinese biotech company with limited public information available, making due diligence challenging. The company appears to maintain a low profile with no readily accessible data on pipeline assets, recent deals, or key management personnel. While currently clear of BIOSECURE designation, the lack of transparency and corporate information raises concerns about deal readiness and partnership potential for US BD teams.
Structure: Corporate structure is unclear due to limited available information, though the Shanghai incorporation suggests it may operate as a domestic Chinese entity rather than through VIE structures. The absence of publicly disclosed subsidiary information or holding company relationships makes it difficult to assess the full corporate architecture for due diligence purposes.
BIOSECURE Risk
While currently clear of BIOSECURE designation, the lack of transparency and limited public disclosure creates uncertainty about potential future exposure
Key Exposures:
- •Limited corporate transparency
- •Unknown government relationships
- •Unclear funding sources
Mitigation: No public information available on BIOSECURE compliance measures or risk mitigation strategies
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity identified
Approach: Exercise extreme caution and conduct thorough preliminary due diligence before any formal engagement due to limited available information
Red Flags
- ⚠Lack of publicly available corporate information
- ⚠No disclosed key management personnel
- ⚠Absence of pipeline or therapeutic area data
- ⚠No track record of international partnerships
- ⚠Limited transparency for due diligence
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.